Killing More Cancerous Cells than Healthy at Thomas Jefferson University

Killing More Cancerous Cells than Healthy at Thomas Jefferson University
Research in the laboratory of Ulrich Rodeck, MD, PhD, at Thomas Jefferson University, is looking to make prostate cancer (and other cancer types) radiation therapy safer and more effective for patients. Dr. Rodeck’s work with a new anti-cancer drug, RTA-408, currently being developed by Reata Pharmaceuticals, is directed toward protecting normal cells from radiation while

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , .

Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Leave a Comment

Your email address will not be published. Required fields are marked *